Latest in Neumora
Sort by
1 items
-
Neumora Therapeutics’ stock craters after trial of major depressive disorder fails to meet main goals
The news is a setback for the clinical-stage biotech and a drug that proved successful in earlier trials.MarketWatch - 6d